title: [What's new concerning the chemobrain?].
abstract: Chemobrain, a subtle cognitive decline after chemotherapy in non-cerebral cancer, remains a debated issue, which has nevertheless been widely described for more than 15 years in the international literature. This phenomenon is almost unknown in France to experts, neurologists and oncologists. Experimental evidence from animal models and from human functional imagery is reliable but contrasts with the observations made during clinical studies. Indeed, in clinical practice, the difficulty in proving the occurrence of chemobrain may be explained by a large number of methodological skews. However, considering the International Cognition and Cancer Task Force (ICCTF) guidelines, we propose a methodology applicable in daily practice and capable of improving awareness of this phenomenon.
authors.affiliation: Service de neurologie, hôpital d'instruction des armées du Val-de-Grâce, 74, boulevard de Port-Royal, 75005 Paris, France. herve.taillia@santarm.fr
authors.forename: H
authors.initials: H
authors.lastname: Taillia
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001921:Brain / Q000187:drug effects* / Q000503:physiopathology; D003072:Cognition Disorders / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D023421:Models, Animal; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D009462:Neurology / Q000379:methods / Q000639:trends*; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents